CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 3 enrolled
Drug / intervention
carbidopa/l-dopa +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00200447
NCT00200447Phase 2Completed
CompareCT.gov

Assessment of Carbidopa/l-Dopa and Carbidopa/l Dopa/Entacapone on Synaptic Dopamine in Parkinson's Patients: An Open-Label Feasibility/Pilot Study With [123I]-IBZM SPECT (DOPA-SYN)

Molecular NeuroImaging·interventional·Posted Sep 20, 2005·Updated Jan 21, 2008

In Brief

A Phase 2 clinical trial evaluating carbidopa/l-dopa, carbidopa/l-dopa/entacapone, and 2 other interventions for Parkinson's Disease. Completed, enrolled 3 participants.

Detailed Summary

This study conducted to more fully evaluate the way that carbidopa/levodopa and entacapone may work in the brain. This research study uses \[123I\]-IBZM and dynamic SPECT imaging to determine the amount and the duration of dopamine release from specific regions in the brain after treatment with either the combination of carbidopa/levodopa or the combination of carbidopa/levodopa/entacapone.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsParkinson's Disease
Countries--
Collaborators--

Timeline

Phase 2CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 20, 2005
Enrollment StartMar 1, 2004
Primary CompletionSep 1, 2004
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 20.8 years ago

Interventions

carbidopa/l-dopadrug

carbidopa/l-dopa/entacaponedrug

Stalevodrug

[123I]-IBZM imagingprocedure